SCHEMBL19494633

SCHEMBL19494633

NC(=O)c1cc([S+]([O-])N2CCOCC2)sc1NC(=O)c1ncco1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.33
▸ MEN1 O00255 5/20 0.33
▸ KMT2A Q03164 5/20 0.33
▸ MAPT P10636 5/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ HSD17B10 Q99714 4/20 0.33
▸ HPGD P15428 3/20 0.33
▸ ALOX15 P16050 3/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ MAPK10 P53779 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CFTR P13569 2/20 0.33
▸ USP2 O75604 3/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ GFER P55789 1/20 0.32
▸ TBK1 Q9UHD2 2/20 0.32
▸ IKBKE Q14164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19494635 0.79 TBK1 (0.35) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL19494912 0.78 CFTR (0.40) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL16338254 0.78 CFTR (0.53) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL16263912 0.77 BCL3 (0.42) ALDH1A1MEN1KMT2AMAPTRAB9A
SCHEMBL16263934 0.76 MAPT (0.33) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL16263801 0.76 L3MBTL1 (0.47) MEN1KMT2AMAPTSMN1; SMN2RAB9A
SCHEMBL16263849 0.76 CNR2 (0.42) ALDH1A1MEN1KMT2AMAPTHPGD
SCHEMBL16263844 0.74 KDM1A (0.36) MEN1KMT2AMAPTKDM4EHSD17B10
SCHEMBL16261720 0.67 RAB9A (0.47) ALDH1A1MEN1KMT2AMAPTKDM4E
SCHEMBL19494388 0.67 MEN1 (0.36) ALDH1A1MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2994463-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS GALAPAGOS NV (BE) 2017-10-25 — — EP disclosed
Send feedback